Dublin, April 02, 2026 (GLOBE NEWSWIRE) — The “Pediatric Neuroblastoma Treatment Market Report 2026” has been added to ResearchAndMarkets.com’s offering. The report provides a detailed analysis of market size, regional shares, competitor strategies, and trends.
The pediatric neuroblastoma treatment market has demonstrated substantial growth, increasing from $2.02 billion in 2025 to a projected $2.2 billion in 2026, at a CAGR of 9%. Historical growth factors include limited access to oncology drugs, low adoption of immunotherapy, reliance on conventional chemotherapy, limited specialized centers, and fragmented clinical data.
Looking forward, the market is expected to reach $3.13 billion by 2030, growing at a 9.2% CAGR. This growth is driven by enhanced R&D in targeted therapies, increased use of CAR T-cell and monoclonal antibodies, rising adoption of personalized medicine, and expanded investment in oncology infrastructure. Other growth catalysts include awareness programs for early detection, AI in diagnostics, genomics-based therapies, cloud and big data integration for patient management, IoT-enabled monitoring, and innovations in drug production.
The growing number of new neuroblastoma cases will significantly drive market expansion. The rising prevalence is fueling demand for effective treatments, motivating pharmaceutical companies to invest in R&D and foster innovation. Advanced diagnostics and screening technologies now allow for earlier neuroblastoma detection, supporting timely interventions and improved clinical outcomes. Data from the American Society of Clinical Oncology highlights that neuroblastoma affects 700 to 800 children annually in the US alone, accounting for 6% of all childhood cancers.
Leading companies are advancing technologies like antibody-based approaches, enhancing therapy effectiveness and patient outcomes. Renaissance Pharma Ltd introduced Hu14.18K322A, targeting GD2 on neuroblastoma cells, enhancing immune attack on tumors. Moreover, Serb Pharmaceuticals’ acquisition of Y-mAbs Therapeutics aims to bolster its pediatric oncology portfolio, particularly through DANYELZA, a flagship anti-GD2 monoclonal antibody for high-risk cases.
Major market players include United Therapeutics Corporation, APEIRON Biologics AG, Pfizer Inc., MacroGenics Inc., Bayer AG, Y-mAbs Therapeutics Inc., Amgen Inc., Eli Lilly, F. Hoffmann-La Roche AG, Novartis AG, Johnson & Johnson, AbbVie Inc., Merck & Co., Bristol-Myers Squibb, Takeda Pharmaceutical, Daiichi Sankyo, and Eisai Co.
In 2025, North America led the market. Regions covered include Asia-Pacific, Europe, North and South America, the Middle East, and Africa. Countries in focus include the US, UK, Germany, France, China, India, and Japan.
Reasons to Purchase:
- Gain a comprehensive global perspective by exploring 16 geographical markets.
- Analyze macro factors such as geopolitical issues, trade policies, inflation, interest rate shifts, and regulatory changes.
- Formulate regional and country-level strategies based on local insights.
- Pinpoint investment opportunities in growth sectors.
- Utilize accurate forecast data to outperform market competitors.
- Enhance customer understanding through detailed end-user analysis.
- Benchmark against major competitors using market share, innovation metrics, and brand analysis.
- Calculate the total addressable market (TAM) and assess its attractiveness.
- Support presentations with reliable data and analysis.
- Receive updates with the newest data accompanied by an Excel data sheet for robust analysis.
- Access data through an interactive Excel dashboard.
Report Scope:
- Markets Covered: By Treatment Type: Immunotherapy, Chemotherapy, Radiation Therapy, Other Treatments
- Risk Groups: Low, Intermediate, High
- End Users: Hospitals, Specialty Clinics
Companies: United Therapeutics Corporation, APEIRON Biologics AG, Pfizer Inc., Bayer AG, Amgen Inc., Novartis AG, and more.
Countries: Australia, Brazil, China, France, India, Japan, Taiwan, UK, USA, among others.
Regions: Asia-Pacific, Western Europe, North America, Middle East, Africa
Time Series: Five years historic and ten years forecast.
Key Attributes
| Report Attribute | Details |
| No. of Pages | 250 |
| Forecast Period | 2026-2030 |
| Estimated Market Value (USD) in 2026 | $2.2 Billion |
| Forecasted Market Value (USD) by 2030 | $3.13 Billion |
| Compound Annual Growth Rate | 9.2% |
| Regions Covered | Global |
The companies featured in this Pediatric Neuroblastoma Treatment market report include:
- United Therapeutics Corporation
- APEIRON Biologics AG
- Cell Ectar Biosciences Inc.
- Pfizer Inc.
- MacroGenics Inc.
- Bayer AG
- Provectus Biopharmaceuticals Inc.
- Y-mAbs Therapeutics Inc.
- Amgen Inc.
- Eli Lilly and Company
- F. Hoffmann-La Roche AG
- Clarity Pharmaceuticals
- CureSearch for Children’s Cancer
- Novartis AG
- Johnson & Johnson Services Inc.
- AbbVie Inc.
- Merck & Co. Inc.
- Bristol-Myers Squibb Company
- Takeda Pharmaceutical Company Limited
- Daiichi Sankyo Company Limited
- Eisai Co. Ltd.
For more information about this report visit https://www.researchandmarkets.com/r/wahoih
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Pediatric Neuroblastoma Treatment Market
